JP2010522170A - ４’−ｏ−置換イソインドリン誘導体および該誘導体を含有する組成物およびその使用方法 - Google Patents

４’−ｏ−置換イソインドリン誘導体および該誘導体を含有する組成物およびその使用方法 Download PDF

Info

Publication number
JP2010522170A
JP2010522170A JP2009554563A JP2009554563A JP2010522170A JP 2010522170 A JP2010522170 A JP 2010522170A JP 2009554563 A JP2009554563 A JP 2009554563A JP 2009554563 A JP2009554563 A JP 2009554563A JP 2010522170 A JP2010522170 A JP 2010522170A
Authority
JP
Japan
Prior art keywords
mmol
compound
disease
mixture
limited
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009554563A
Other languages
English (en)
Japanese (ja)
Inventor
ルチェルマン，アレクサンダー，エル．
ミュラー，ジョージ，ダブリュ．
マン，ホン−ワ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39719168&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2010522170(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of JP2010522170A publication Critical patent/JP2010522170A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
JP2009554563A 2007-03-20 2008-03-19 ４’−ｏ−置換イソインドリン誘導体および該誘導体を含有する組成物およびその使用方法 Withdrawn JP2010522170A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91932307P 2007-03-20 2007-03-20
PCT/US2008/003602 WO2008115516A2 (en) 2007-03-20 2008-03-19 4'-o-substituted isoindoline derivatives and compositions comprising and methods of using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014129790A Division JP5927241B2 (ja) 2007-03-20 2014-06-25 ４’−ｏ−置換イソインドリン誘導体および該誘導体を含有する組成物およびその使用方法

Publications (1)

Publication Number Publication Date
JP2010522170A true JP2010522170A (ja) 2010-07-01

Family

ID=39719168

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2009554563A Withdrawn JP2010522170A (ja) 2007-03-20 2008-03-19 ４’−ｏ−置換イソインドリン誘導体および該誘導体を含有する組成物およびその使用方法
JP2014129790A Active JP5927241B2 (ja) 2007-03-20 2014-06-25 ４’−ｏ−置換イソインドリン誘導体および該誘導体を含有する組成物およびその使用方法
JP2015211991A Active JP6373818B2 (ja) 2007-03-20 2015-10-28 ４’−ｏ−置換イソインドリン誘導体および該誘導体を含有する組成物およびその使用方法
JP2017155657A Active JP6448726B2 (ja) 2007-03-20 2017-08-10 ４’−ｏ−置換イソインドリン誘導体および該誘導体を含有する組成物およびその使用方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2014129790A Active JP5927241B2 (ja) 2007-03-20 2014-06-25 ４’−ｏ−置換イソインドリン誘導体および該誘導体を含有する組成物およびその使用方法
JP2015211991A Active JP6373818B2 (ja) 2007-03-20 2015-10-28 ４’−ｏ−置換イソインドリン誘導体および該誘導体を含有する組成物およびその使用方法
JP2017155657A Active JP6448726B2 (ja) 2007-03-20 2017-08-10 ４’−ｏ−置換イソインドリン誘導体および該誘導体を含有する組成物およびその使用方法

Country Status (25)

Country Link
US (6) US8153659B2 (enExample)
EP (2) EP3101017B1 (enExample)
JP (4) JP2010522170A (enExample)
KR (3) KR101791757B1 (enExample)
CN (2) CN101679380A (enExample)
AR (1) AR065810A1 (enExample)
AU (1) AU2008229383B2 (enExample)
BR (1) BRPI0809011A8 (enExample)
CA (1) CA2681633C (enExample)
CL (1) CL2008000805A1 (enExample)
CO (1) CO6231033A2 (enExample)
CR (2) CR11036A (enExample)
EC (1) ECSP099663A (enExample)
ES (2) ES2734253T3 (enExample)
IL (1) IL200990A (enExample)
MX (1) MX2009010082A (enExample)
MY (1) MY180812A (enExample)
NI (1) NI200900170A (enExample)
NZ (2) NZ579890A (enExample)
PE (1) PE20081894A1 (enExample)
RU (1) RU2471794C2 (enExample)
UA (1) UA97976C2 (enExample)
UY (1) UY30977A1 (enExample)
WO (1) WO2008115516A2 (enExample)
ZA (1) ZA200906497B (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017533955A (ja) * 2014-10-30 2017-11-16 カンプー バイオファーマシューティカルズ リミテッド イソインドリン誘導体、その中間体、製造方法、薬物組成物及び応用
JP2021524484A (ja) * 2018-07-10 2021-09-13 ノバルティス アーゲー ３−（５−ヒドロキシ−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオン誘導体及びＩｋａｒｏｓファミリージンクフィンガー２（ＩＫＺＦ２）依存性疾患の処置におけるその使用
JP2022503942A (ja) * 2018-09-30 2022-01-12 上海 インスティテュート オブ マテリア メディカ、チャイニーズ アカデミー オブ サイエンシーズ イソインドリン化合物、その調製方法、医薬組成物および使用
JP2022521227A (ja) * 2019-02-22 2022-04-06 エルケム・シリコーンズ・ユーエスエイ・コーポレーション 有効成分の溶出を改善するための薬デリバリーシリコーン組成物
JP2023525951A (ja) * 2020-02-25 2023-06-20 シャンハイテック ユニバーシティ グルタルイミド骨格に基づく化合物及びその使用
US12564638B2 (en) 2019-08-05 2026-03-03 Shanghaitech University EGFR protein degradant and anti-tumor application thereof
US12582641B2 (en) 2019-02-25 2026-03-24 Shanghaitech University Sulfur-containing compound based on glutarimide skeleton and application thereof

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2929331B2 (ja) * 1990-07-18 1999-08-03 丸善石油化学株式会社 トラクションドライブ用流体
CN101111234A (zh) * 2004-12-01 2008-01-23 细胞基因公司 包含免疫调节化合物的组合物及其治疗免疫缺陷疾病的用途
KR101791757B1 (ko) 2007-03-20 2017-10-30 셀진 코포레이션 4'-ｏ-치환된 아이소인돌린 유도체 및 이를 포함하는 조성물 및 이의 사용 방법
US7964354B2 (en) * 2007-12-20 2011-06-21 Celgene Corporation Use of micro-RNA as a biomarker of immunomodulatory drug activity
AU2010327936B2 (en) 2009-12-11 2015-08-20 Nono Inc. Agents and methods for treating ischemic and other diseases
PL2536706T3 (pl) * 2010-02-11 2017-10-31 Celgene Corp Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania
AU2013245487B2 (en) * 2010-02-11 2016-03-10 Celgene Corporation Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
AU2016203826B2 (en) * 2010-02-11 2018-05-17 Celgene Corporation Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
WO2012135299A1 (en) 2011-03-28 2012-10-04 Deuteria Pharmaceuticals Inc 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
EP2720695A4 (en) * 2011-06-15 2014-11-12 Nono Inc ACTIVE AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES
CN102731853B (zh) * 2012-06-28 2013-11-27 芜湖宏达橡塑阀门制造有限公司 耐油橡胶
CN102731850B (zh) * 2012-06-28 2013-11-27 芜湖宏达橡塑阀门制造有限公司 耐油耐磨橡胶
CN102731851B (zh) * 2012-06-28 2013-11-27 芜湖宏达橡塑阀门制造有限公司 一种耐油橡胶
US9133161B2 (en) * 2012-07-27 2015-09-15 Celgene Corporation Processes for preparing isoindoline-1,3-dione compounds
US20150038511A1 (en) 2012-08-09 2015-02-05 Celgene Corporation Treatment of immune-related and inflammatory diseases
PT2882441T (pt) 2012-08-09 2020-06-29 Celgene Corp Tratamento de doenças associadas à imunidade e inflamatórias
SG11201500984QA (en) 2012-08-09 2015-04-29 Celgene Corp Processes for the preparation of (s)-3-4-((4-(morpholinomethyl) benzyl)oxy)-1-oxoisoindolin-2-yl) piperidine-2,6-dione and pharmaceutically acceptable forms thereof
JP6347782B2 (ja) * 2012-08-09 2018-06-27 セルジーン コーポレイション ３−（４−（（４−（モルホリノメチル）ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオンを使用する癌の治療方法
US9540340B2 (en) 2013-01-14 2017-01-10 Deuterx, Llc 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same
US9695145B2 (en) 2013-01-22 2017-07-04 Celgene Corporation Processes for the preparation of isotopologues of 3-(4-((4- morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
US9242966B2 (en) 2013-03-11 2016-01-26 Bristol-Myers Squibb Company Phthalazines as potassium ion channel inhibitors
US9290475B2 (en) 2013-03-14 2016-03-22 Deuterx, Llc 3-(substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same
AU2014254056B2 (en) 2013-04-17 2019-06-06 Signal Pharmaceuticals, Llc Combination therapy comprising a TOR kinase inhibitor and an IMiD compound for treating cancer
UA117141C2 (uk) 2013-10-08 2018-06-25 Селджин Корпорейшн Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону
ES2969532T3 (es) 2014-05-19 2024-05-21 Celgene Corp 3-(4-((4-(Morfolinometil-bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona para el tratamiento de lupus eritematoso sistémico
US9809603B1 (en) 2015-08-18 2017-11-07 Deuterx, Llc Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
US10231959B2 (en) 2016-03-23 2019-03-19 Louis Habash Increasing expression level of apoptosis-related genes by treating a human subject with a nitroxide
US20180078539A1 (en) 2016-03-23 2018-03-22 Louis Habash T-cell regulation in t-cell mediated diseases by reducing pathogenic function of th17 in a human subject through treatment with a nitroxide
WO2017165572A1 (en) * 2016-03-23 2017-09-28 Louis Habash Increasing expression level of apoptosis-related genes by treating a human subject with a nitroxide
US10159665B2 (en) 2016-03-23 2018-12-25 Louis Habash Preventing amyloid plaque formation by treating a human subject with a nitroxide
ES2989988T3 (es) 2016-05-10 2024-11-28 C4 Therapeutics Inc Degronímeros heterorocíclicos para la degradación de proteínas diana
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
WO2017197051A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
KR20220028178A (ko) * 2016-12-16 2022-03-08 강푸 바이오파마슈티칼즈 리미티드 조성물, 이의 적용 및 치료 방법
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
WO2019014100A1 (en) 2017-07-10 2019-01-17 Celgene Corporation ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF
CN111278816B (zh) 2017-09-04 2024-03-15 C4医药公司 二氢喹啉酮
EP3679026A1 (en) 2017-09-04 2020-07-15 C4 Therapeutics, Inc. Glutarimide
CN111315735B (zh) 2017-09-04 2024-03-08 C4医药公司 二氢苯并咪唑酮
EP3710002A4 (en) 2017-11-16 2021-07-07 C4 Therapeutics, Inc. DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION
CN111902141A (zh) 2018-03-26 2020-11-06 C4医药公司 用于ikaros降解的羟脑苷脂结合剂
EP3778590A4 (en) * 2018-04-09 2021-12-22 ShanghaiTech University ANTI PROTEIN DEGRADATION COMPOUND, ANTITUMOR APPLICATION, INTERMEDIATE THEREOF, AND INTERMEDIATE USE
CN112312904B (zh) 2018-04-16 2025-01-07 C4医药公司 螺环化合物
SG11202009237XA (en) 2018-04-23 2020-10-29 Celgene Corp Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma
EP3578561A1 (en) 2018-06-04 2019-12-11 F. Hoffmann-La Roche AG Spiro compounds
US11529339B2 (en) 2018-10-01 2022-12-20 Celgene Corporation Combination therapy for the treatment of cancer
WO2020092950A1 (en) * 2018-11-01 2020-05-07 Northwestern University Targeting pleckstrin-2 for treating cancer
EP3891128A4 (en) * 2018-12-05 2022-08-17 Vividion Therapeutics, Inc. SUBSTITUTED ISOINDOLINONES AS MODULATORS OF CEREBLON-MEDIATED NEOSUBSTRATE RECRUITMENT
CN111285850B (zh) 2018-12-06 2022-04-22 中国科学院上海药物研究所 一类异吲哚啉类化合物、其制备方法、药物组合物及其应用
CN120698983A (zh) 2018-12-20 2025-09-26 C4医药公司 靶向蛋白降解
WO2020181232A1 (en) 2019-03-06 2020-09-10 C4 Therapeutics, Inc. Heterocyclic compounds for medical treatment
CN111747924B (zh) * 2019-03-29 2023-11-10 华东师范大学 一类来那度胺/泊马度胺类似物及其应用
KR20210152515A (ko) 2019-04-12 2021-12-15 씨4 테라퓨틱스, 인코포레이티드 이카로스 및 아이올로스의 트리시클릭 분해제
SG11202110085TA (en) 2019-05-31 2021-10-28 Sichuan Haisco Pharmaceutical Co Ltd Btk inhibitor ring derivative, preparation method therefor and pharmaceutical application thereof
KR20230004493A (ko) * 2020-04-17 2023-01-06 에시언트 파마슈티컬스 인코포레이티드 Mas-관련 G-단백질 수용체 X4의 조절제 및 관련 제품 및 방법
JP2023534528A (ja) * 2020-07-20 2023-08-09 江蘇恒瑞医薬股▲ふん▼有限公司 硫黄含有イソインドリン系誘導体、その調製方法及びその医薬的応用
CN116669736B (zh) * 2021-01-05 2025-11-11 江苏恒瑞医药股份有限公司 稠杂环基取代的环己二酰亚胺衍生物、其制备方法及其在医药上的应用
MX2023008296A (es) 2021-01-13 2023-09-29 Monte Rosa Therapeutics Inc Compuestos de isoindolinona.
CN115504963A (zh) * 2021-06-22 2022-12-23 苏州开拓药业股份有限公司 一种c-Myc蛋白降解剂
US20250154126A1 (en) 2022-01-19 2025-05-15 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Crystalline form of sulfur-containing isoindoline derivative
EP4536656A1 (en) 2022-06-06 2025-04-16 C4 Therapeutics, Inc. Bicyclic-substituted glutarimide cereblon binders
AR130961A1 (es) 2022-11-04 2025-02-05 Bristol Myers Squibb Co Compuestos y su uso para el tratamiento de hemoglobinopatías
CN116675786A (zh) * 2023-07-10 2023-09-01 盐城师范学院 一种靶向传递喜树碱的环糊精超分子药物及其制备方法和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998042666A1 (en) * 1997-03-21 1998-10-01 Daewoong Pharmaceutical Co., Ltd. Novel 3,4-dialkoxyphenyl derivatives and the use thereof
JP2002506861A (ja) * 1998-03-16 2002-03-05 コルジーン コーポレイション ２−（２，６−ジオキソピペリジン−３−イル）イソインドリン誘導体、その製剤および炎症性サイトカイン阻害剤としてのその使用
WO2005042502A1 (en) * 2003-10-24 2005-05-12 Astrazeneca Ab Amide derivatives
WO2006067444A1 (en) * 2004-12-24 2006-06-29 Astrazeneca Ab Amide derivatives
JP2007505922A (ja) * 2003-09-17 2007-03-15 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ サリドマイド類似体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994443A (en) 1982-12-20 1991-02-19 The Children's Medical Center Corporation Inhibition of angiogenesis
US5001116A (en) 1982-12-20 1991-03-19 The Children's Medical Center Corporation Inhibition of angiogenesis
US5800819A (en) 1996-01-25 1998-09-01 National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease
US6458810B1 (en) * 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
US20030045552A1 (en) * 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
US7320992B2 (en) * 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
CN101111234A (zh) 2004-12-01 2008-01-23 细胞基因公司 包含免疫调节化合物的组合物及其治疗免疫缺陷疾病的用途
KR101791757B1 (ko) * 2007-03-20 2017-10-30 셀진 코포레이션 4'-ｏ-치환된 아이소인돌린 유도체 및 이를 포함하는 조성물 및 이의 사용 방법

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998042666A1 (en) * 1997-03-21 1998-10-01 Daewoong Pharmaceutical Co., Ltd. Novel 3,4-dialkoxyphenyl derivatives and the use thereof
JP2002506861A (ja) * 1998-03-16 2002-03-05 コルジーン コーポレイション ２−（２，６−ジオキソピペリジン−３−イル）イソインドリン誘導体、その製剤および炎症性サイトカイン阻害剤としてのその使用
JP2007505922A (ja) * 2003-09-17 2007-03-15 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ サリドマイド類似体
WO2005042502A1 (en) * 2003-10-24 2005-05-12 Astrazeneca Ab Amide derivatives
WO2006067444A1 (en) * 2004-12-24 2006-06-29 Astrazeneca Ab Amide derivatives

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JPN6013014117; Ｓｈｏｊｉ Ａ． ｅｔ ａｌ: Ｊ． ＡＭ． ＣＨＥＭ． ＳＯＣ． Ｖｏｌ．１２９ Ｎｏ．５, 20070207, ｐ．１４５６-１４６４ *
JPN6013014120; Ｗｅｉｎｔｚ　Ｃ．　ｅｔ　ａｌ: Ｊ．　Ｃｈｒｏｍａｔｏｇｒ．　Ｂ Ｖｏｌ．６７４, 1995, ２８７-２９２ *
JPN6013014126; ＮＡＫＡＭＵＲＡ，Ｔ． ｅｔ ａｌ: 'Ｍｏｎｏ- ａｎｄ ｄｉｈｙｄｒｏｘｙｌａｔｅｄ ｍｅｔａｂｏｌｉｔｅｓ ｏｆ ｔｈａｌｉｄｏｍｉｄｅ： ｓｙｎｔｈｅｓｉｓ ａｎｄ ＴＮＦ-alpha ｐｒｏｄｕｃｔｉｏｎ-ｉｎｈｉｂｉｔｏｒｙ ａｃｔ' Ｃｈｅｍｉｃａｌ ＆ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｂｕｌｌｅｔｉｎ Ｖｏｌ．５４， Ｎｏ．１２, 2006, ｐ．１７０９-１７１４ *
JPN7013001106; Ｍａｒｋｓ　Ｍ．　Ｇ．　ｅｔ　ａｌ: Ｂｉｏｌ．　Ｐｈａｒｍ．　Ｂｕｌｌ． Ｖｏｌ．２５　Ｎｏ．５, 2002, ｐ．５９７-６０４ *
JPN7013001107; ＭＥＮＡＲＤ，Ｍ．　ｅｔ　ａｌ: 'Ｓｏｍｅ　ｐｏｓｓｉｂｌｅ　ｍｅｔａｂｏｌｉｔｅｓ　ｏｆ　ｔｈａｌｉｄｏｍｉｄｅ' Ｃａｎａｄｉａｎ　Ｊｏｕｒｎａｌ　ｏｆ　Ｃｈｅｍｉｓｔｒｙ Ｖｏｌ．４１，　Ｎｏ．７, 1963, ｐ．１７２２-１７２５ *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017533955A (ja) * 2014-10-30 2017-11-16 カンプー バイオファーマシューティカルズ リミテッド イソインドリン誘導体、その中間体、製造方法、薬物組成物及び応用
JP2021524484A (ja) * 2018-07-10 2021-09-13 ノバルティス アーゲー ３−（５−ヒドロキシ−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオン誘導体及びＩｋａｒｏｓファミリージンクフィンガー２（ＩＫＺＦ２）依存性疾患の処置におけるその使用
JP2024147561A (ja) * 2018-07-10 2024-10-16 ノバルティス アーゲー ３－（５－ヒドロキシ－１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びＩｋａｒｏｓファミリージンクフィンガー２（ＩＫＺＦ２）依存性疾患の処置におけるその使用
JP7640450B2 (ja) 2018-07-10 2025-03-05 ノバルティス アーゲー ３－（５－ヒドロキシ－１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びＩｋａｒｏｓファミリージンクフィンガー２（ＩＫＺＦ２）依存性疾患の処置におけるその使用
JP2022503942A (ja) * 2018-09-30 2022-01-12 上海 インスティテュート オブ マテリア メディカ、チャイニーズ アカデミー オブ サイエンシーズ イソインドリン化合物、その調製方法、医薬組成物および使用
JP7168773B2 (ja) 2018-09-30 2022-11-09 上海 インスティテュート オブ マテリア メディカ、チャイニーズ アカデミー オブ サイエンシーズ イソインドリン化合物、その調製方法、医薬組成物および使用
JP2022521227A (ja) * 2019-02-22 2022-04-06 エルケム・シリコーンズ・ユーエスエイ・コーポレーション 有効成分の溶出を改善するための薬デリバリーシリコーン組成物
JP7524203B2 (ja) 2019-02-22 2024-07-29 エルケム・シリコーンズ・ユーエスエイ・コーポレーション 有効成分の溶出を改善するための薬デリバリーシリコーン組成物
US12582641B2 (en) 2019-02-25 2026-03-24 Shanghaitech University Sulfur-containing compound based on glutarimide skeleton and application thereof
US12564638B2 (en) 2019-08-05 2026-03-03 Shanghaitech University EGFR protein degradant and anti-tumor application thereof
JP2023525951A (ja) * 2020-02-25 2023-06-20 シャンハイテック ユニバーシティ グルタルイミド骨格に基づく化合物及びその使用
JP7477076B2 (ja) 2020-02-25 2024-05-01 シャンハイテック ユニバーシティ グルタルイミド骨格に基づく化合物及びその使用

Also Published As

Publication number Publication date
EP3101017B1 (en) 2019-06-12
JP5927241B2 (ja) 2016-06-01
IL200990A0 (en) 2010-05-17
CO6231033A2 (es) 2010-12-20
CN103641814A (zh) 2014-03-19
ECSP099663A (es) 2009-10-30
US20140073669A1 (en) 2014-03-13
WO2008115516A3 (en) 2008-11-13
UY30977A1 (es) 2008-10-31
JP2018021046A (ja) 2018-02-08
EP3101017A1 (en) 2016-12-07
RU2471794C2 (ru) 2013-01-10
US20180155316A1 (en) 2018-06-07
BRPI0809011A2 (pt) 2014-09-16
AU2008229383B2 (en) 2013-09-05
KR20170093996A (ko) 2017-08-16
JP2016065067A (ja) 2016-04-28
US8614328B2 (en) 2013-12-24
KR20150046384A (ko) 2015-04-29
NZ599199A (en) 2013-10-25
RU2009138500A (ru) 2011-04-27
US9920027B2 (en) 2018-03-20
CN101679380A (zh) 2010-03-24
US8153659B2 (en) 2012-04-10
US20090004209A1 (en) 2009-01-01
US20120165536A1 (en) 2012-06-28
UA97976C2 (ru) 2012-04-10
KR101791757B1 (ko) 2017-10-30
MX2009010082A (es) 2009-10-19
JP2014224118A (ja) 2014-12-04
USRE46639E1 (en) 2017-12-19
ZA200906497B (en) 2010-11-24
JP6448726B2 (ja) 2019-01-09
CA2681633A1 (en) 2008-09-25
JP6373818B2 (ja) 2018-08-15
NZ579890A (en) 2012-05-25
IL200990A (en) 2016-05-31
CL2008000805A1 (es) 2009-05-22
CR11036A (es) 2009-10-06
NI200900170A (es) 2010-09-09
AU2008229383A1 (en) 2008-09-25
WO2008115516A8 (en) 2008-12-31
US20160024048A1 (en) 2016-01-28
PE20081894A1 (es) 2009-01-26
KR20090121400A (ko) 2009-11-25
EP2142534A2 (en) 2010-01-13
CR20140368A (es) 2014-08-25
MY180812A (en) 2020-12-09
US9181216B2 (en) 2015-11-10
US10385037B2 (en) 2019-08-20
AR065810A1 (es) 2009-07-01
EP2142534B1 (en) 2016-08-10
ES2734253T3 (es) 2019-12-05
WO2008115516A2 (en) 2008-09-25
BRPI0809011A8 (pt) 2019-01-15
CA2681633C (en) 2018-01-09
ES2601131T3 (es) 2017-02-14

Similar Documents

Publication Publication Date Title
JP6448726B2 (ja) ４’−ｏ−置換イソインドリン誘導体および該誘導体を含有する組成物およびその使用方法
JP6133383B2 (ja) ５−置換キナゾリノン誘導体、それを含む組成物、及びその使用方法
JP5637852B2 (ja) ６、７又は８置換キナゾリノン誘導体並びにそれらを含有する組成物及びそれらを使用する方法
JP5567339B2 (ja) Ｎ−メチルアミノメチルイソインドール化合物、それを含む組成物、及びその使用方法
RU2448101C2 (ru) 5-замещенные изоиндолиновые соединения
AU2013260742B2 (en) 4'-o-substituted isoindoline derivatives and compositions comprising and methods of using the same
RS56117B1 (sr) Derivati 5-supstituisanog hinazolinona kao antikancer agensi

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110317

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130326

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130625

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130702

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130925

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140625

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20140801